The association between non-alcoholic fatty liver disease (with or without metabolic syndrome) and extrahepatic cancer development.
Helicobacter pylori
International Statistical Classification of Diseases
dysbiosis
insulin resistance
metabolic syndrome
neoplasm
non-alcoholic fatty liver disease
small intestinal bacterial overgrowth
Journal
Journal of gastroenterology and hepatology
ISSN: 1440-1746
Titre abrégé: J Gastroenterol Hepatol
Pays: Australia
ID NLM: 8607909
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
17
10
2020
received:
09
07
2020
accepted:
07
11
2020
pubmed:
18
11
2020
medline:
15
12
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
This study was designed to determine whether non-alcoholic fatty liver disease (NAFLD), with or without metabolic syndrome (MetS), is a risk factor for cancer development. We conducted a retrospective longitudinal study at the Center for Preventive Medicine, St. Luke's International Hospital. Among all participants who underwent a health checkup between 2005 and 2019, cancer development tendencies were compared between those who were diagnosed with NAFLD and those who were not. Further evaluation was conducted among NAFLD-diagnosed participants with versus without MetS in the same manner. Those with a history of a specific liver disease, any type of cancer, or alcohol consumption in any amount at the time of the initial visit were excluded from the study. Data were collected from 30 172 participants who underwent health checkups, among whom 4394 (14.6%) had NAFLD. Over the 14-year follow-up period, 2086 participants (6.9%) developed cancer. Participants with NAFLD had a higher incidence of digestive organ neoplasms (odds ratio [OR]: 1.34, 95% confidence interval [CI]: 1.07-1.67), especially in the stomach (OR: 1.40, 95% CI: 1.02-1.94) and small intestine (OR: 2.80, 95% CI: 0.87-8.96), than did those without NAFLD. Participants with NAFLD and MetS had significantly lower rates of neoplasms in respiratory and intrathoracic organs (OR: 0.35 95% CI: 0.14-0.88) and male genital organs (OR: 0.46 95% CI: 0.24-0.87) than did individuals without NAFLD. Non-alcoholic fatty liver disease is associated with the development of gastrointestinal malignancies, while MetS is a negative risk factor for lung and prostate cancer.
Sections du résumé
BACKGROUND AND AIM
OBJECTIVE
This study was designed to determine whether non-alcoholic fatty liver disease (NAFLD), with or without metabolic syndrome (MetS), is a risk factor for cancer development.
METHODS
METHODS
We conducted a retrospective longitudinal study at the Center for Preventive Medicine, St. Luke's International Hospital. Among all participants who underwent a health checkup between 2005 and 2019, cancer development tendencies were compared between those who were diagnosed with NAFLD and those who were not. Further evaluation was conducted among NAFLD-diagnosed participants with versus without MetS in the same manner. Those with a history of a specific liver disease, any type of cancer, or alcohol consumption in any amount at the time of the initial visit were excluded from the study.
RESULTS
RESULTS
Data were collected from 30 172 participants who underwent health checkups, among whom 4394 (14.6%) had NAFLD. Over the 14-year follow-up period, 2086 participants (6.9%) developed cancer. Participants with NAFLD had a higher incidence of digestive organ neoplasms (odds ratio [OR]: 1.34, 95% confidence interval [CI]: 1.07-1.67), especially in the stomach (OR: 1.40, 95% CI: 1.02-1.94) and small intestine (OR: 2.80, 95% CI: 0.87-8.96), than did those without NAFLD. Participants with NAFLD and MetS had significantly lower rates of neoplasms in respiratory and intrathoracic organs (OR: 0.35 95% CI: 0.14-0.88) and male genital organs (OR: 0.46 95% CI: 0.24-0.87) than did individuals without NAFLD.
CONCLUSIONS
CONCLUSIONS
Non-alcoholic fatty liver disease is associated with the development of gastrointestinal malignancies, while MetS is a negative risk factor for lung and prostate cancer.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1971-1978Informations de copyright
© 2020 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140: 124-131.
Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313: 2263-2273.
Eguchi Y, Hyogo H, Ono M et al. Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study. J. Gastroenterol. 2012; 47: 586-595.
Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J. Gastroenterol. 2011; 46: 63-69.
Jimba S, Nakagami T, Takahashi M et al. Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults. Diabet. Med. 2005; 22: 1141-1145.
Chalasani N, Younossi Z, Lavine JE et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012; 142: 1592-1609.
Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 2017; 66: 1138-1153.
Golabi P, Rhea L, Henry L, Younossi ZM. Hepatocellular carcinoma and non-alcoholic fatty liver disease. Hepatol Int. 2019; 13: 688-694.
Cornejo A, Salgado F, Caballero J, Vargas R, Simirgiotis M, Areche C. Secondary metabolites in Ramalina terebrata detected by UHPLC/ESI/MS/MS and identification of parietin as tau protein inhibitor. Int. J. Mol. Sci. 2016; 17.
Liou I, Kowdley KV. Natural history of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006; 40: S11-S16.
Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N. Engl. J. Med. 2000; 343: 1467-1476.
Ahn JS, Sinn DH, Min YW et al. Non-alcoholic fatty liver diseases and risk of colorectal neoplasia. Aliment. Pharmacol. Ther. 2017; 45: 345-353.
Lin XF, Shi KQ, You J et al. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol. Biol. Rep. 2014; 41: 2989-2997.
Mantovani A, Dauriz M, Byrne CD et al. Association between nonalcoholic fatty liver disease and colorectal tumours in asymptomatic adults undergoing screening colonoscopy: a systematic review and meta-analysis. Metabolism 2018; 87: 1-12.
Sanna C, Rosso C, Marietti M, Bugianesi E. Non-alcoholic fatty liver disease and extra-hepatic cancers. Int. J. Mol. Sci. 2016; 17.
Beddy P, Howard J, McMahon C et al. Association of visceral adiposity with oesophageal and junctional adenocarcinomas. Br. J. Surg. 2010; 97: 1028-1034.
Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett's esophagus. Gastroenterology. 2007; 133: 34-41; quiz 311.
Hamaguchi M, Hashimoto Y, Obora A, Kojima T, Fukui M. Non-alcoholic fatty liver disease with obesity as an independent predictor for incident gastric and colorectal cancer: a population-based longitudinal study. BMJ Open Gastroenterol. 2019; 6: e000295.
Lee JM, Park YM, Yun JS et al. The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: national population-based cohort study. PLoS One. 2020; 15: e0226351.
Seko Y, Sumida Y, Tanaka S et al. Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease. Hepatol. Res. 2015; 45: 728-738.
Aune D, Greenwood DC, Chan DS et al. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. Ann. Oncol. 2012; 23: 843-852.
Zhu Y, Wang HK, Zhang HL et al. Visceral obesity and risk of high grade disease in clinical t1a renal cell carcinoma. J. Urol. 2013; 189: 447-453.
Rose DP, Vona-Davis L. Biochemical and molecular mechanisms for the association between obesity, chronic inflammation, and breast cancer. Biofactors 2014; 40: 1-12.
Bilici A, Ozguroglu M, Mihmanli I, Turna H, Adaletli I. A case-control study of non-alcoholic fatty liver disease in breast cancer. Med. Oncol. 2007; 24: 367-371.
McGrowder DA, Jackson LA, Crawford TV. Prostate cancer and metabolic syndrome: is there a link? Asian Pac. J. Cancer Prev. 2012; 13: 1-13.
Schmid D, Ricci C, Behrens G, Leitzmann MF. Adiposity and risk of thyroid cancer: a systematic review and meta-analysis. Obes. Rev. 2015; 16: 1042-1054.
Wang Z, Zhao X, Chen S et al. Associations between nonalcoholic fatty liver disease and cancers in a large cohort in China. Clin. Gastroenterol. Hepatol. 2020.
Syndrome TECoCfM. Definition and criteria of metabolic syndrome. J. Jpn. Soc. Int. Med. 2005; 94: 794-809 (in Japanese).
Stefan N, Haring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endo. 2019; 7: 313-324.
Uzel M, Sahiner Z, Filik L. Non-alcoholic fatty liver disease, metabolic syndrome and gastric cancer: single center experience. J. B.U.ON. 2015; 20: 662.
Yamauchi T, Kamon J, Waki H et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 2001; 7: 941-946.
Gupta K, Krishnaswamy G, Karnad A, Peiris AN. Insulin: a novel factor in carcinogenesis. Am. J. Med. Sci. 2002; 323: 140-145.
Codoner-Franch P, Alonso-Iglesias E. Resistin: insulin resistance to malignancy. Clin. Chim. Acta 2015; 438: 46-54.
Ferrajoli A, Keating MJ, Manshouri T et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood 2002; 100: 1215-1219.
Kai H, Kitadai Y, Kodama M et al. Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of human gastric carcinoma. Anticancer Res. 2005; 25: 709-713.
Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. Ann. N. Y. Acad. Sci. 2012; 1271: 82-87.
Yadav A, Kumar B, Datta J, Teknos TN, Kumar P. IL-6 promotes head and neck tumor metastasis by inducing epithelial-mesenchymal transition via the JAK-STAT3-SNAIL signaling pathway. Mol. Cancer Res. 2011; 9: 1658-1667.
Sethi G, Shanmugam MK, Ramachandran L, Kumar AP, Tergaonkar V. Multifaceted link between cancer and inflammation. Biosci. Rep. 2012; 32: 1-15.
Shanab AA, Scully P, Crosbie O et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig. Dis. Sci. 2011; 56: 1524-1534.
Imajo K, Fujita K, Yoneda M et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell Metab. 2012; 16: 44-54.
Hyde Z, Flicker L, McCaul KA et al. Associations between testosterone levels and incident prostate, lung, and colorectal cancer. A population-based study. Cancer Epidemiol. Biomarkers Prev. 2012; 21: 1319-1329.
Orsted DD, Nordestgaard BG, Bojesen SE. Plasma testosterone in the general population, cancer prognosis and cancer risk: a prospective cohort study. Ann. Oncol. 2014; 25: 712-718.
Blaya R, Blaya P, Rhoden L, Rhoden EL. Low testosterone levels and metabolic syndrome in aging male. Curr. Pharm. Des. 2017; 23: 4470-4474.
Kim S, Kwon H, Park JH et al. A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol. 2012; 12: 69.
Choi WM, Lee JH, Yoon JH et al. Nonalcoholic fatty liver disease is a negative risk factor for prostate cancer recurrence. Endocr. Relat. Cancer 2014; 21: 343-353.
Hernaez R, Lazo M, Bonekamp S et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090.
Polyzos SA, Kountouras J, Papatheodorou A et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease. Metabolism 2013; 62: 121-126.
Gerig R, Ernst B, Wilms B, Thurnheer M, Schultes B. Gastric Helicobacter pylori infection is associated with adverse metabolic traits in severely obese subjects. Obesity (Silver Spring) 2013; 21: 535-537.
Nakajima N, Kozu K, Kobayashi S et al. The expression of IGF-1R in Helicobacter pylori-infected intestinal metaplasia and gastric cancer. J. Clin. Biochem. Nutr. 2016; 59: 53-57.
Eshraghian A, Hashemi SA, Hamidian Jahromi A et al. Helicobacter pylori infection as a risk factor for insulin resistance. Dig. Dis. Sci. 2009; 54: 1966-1970.